How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Vasoactive Intestinal Peptide Tumor Treatment Market
- By Treatment Type: Pharmacological Therapy, Surgical Intervention, Radiation Therapy, Targeted Therapy, Combination Therapy
- By Drug Class: Somatostatin Analogues, Peptide Receptor Radionuclide Therapy (PRRT), Chemotherapeutic Agents, Immunotherapy Agents, Vasoactive Intestinal Peptide (VIP) Antagonists
- By Tumor Type: Neuroendocrine Tumors (NETs), VIPomas, Carcinoid Tumors, Pancreatic Neuroendocrine Tumors (pNETs), Gastrointestinal Neuroendocrine Tumors
- By Patient Population: Adult Patients, Pediatric Patients, Elderly Patients, Patients with Metastatic Disease, Patients with Localized Disease
- By Treatment Setting: Hospital Inpatient, Hospital Outpatient, Specialty Clinics, Home Care
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Pharmacological Therapy leads By Treatment Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 10 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 291 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.184 →
- 12 Company Profiles 10 players: SWOT & benchmarking p.192 →
Full report · locked preview
Everything inside the Vasoactive Intestinal Peptide Tumor Treatment Market report
A complete, evidence-based study - 12 chapters and 122 sections covering market size, segmentation across 5 axes, regional analysis and 10 company profiles, forecast to 2033.
Segmentation covered
Treatment Type 5
Drug Class 5
Tumor Type 5
Patient Population 5
Treatment Setting 4
Companies profiled
Ipsen
Novartis
Ipsen Pharma
Advanced Accelerator Applications (AAA)
TerSera Therapeutics
Mallinckrodt Pharmaceuticals
Novartis AG
Ipsen S.A.
Ipsen Biopharmaceuticals
Ipsen Pharma SAS
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
10 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Ipsen
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Novartis
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Ipsen Pharma
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Advanced Accelerator Applications (AAA)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →TerSera Therapeutics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.178 →Mallinckrodt Pharmaceuticals
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Novartis AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Ipsen S.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Ipsen Biopharmaceuticals
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.202 →Ipsen Pharma SAS
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$3,258M by 2033 · 3.9% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Pharmacological Therapy46.7
- Surgical Intervention16.2
- Radiation Therapy10.3
- Targeted Therapy8.1
- Combination Therapy18.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$793.6M → $1,044M · 3.5%
Europe$553.1M → $717.0M · 3.3%
Asia Pacific$505.0M → $606.3M · 2.3%
Latin America$312.6M → $461.5M · 5.0%
Middle East and Africa$240.5M → $342.8M · 4.5%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →3.812026
3.842027
3.852028
3.862029
3.872030
3.882031
3.902032
3.912033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Ipsen11.1
- Novartis25.8
- Ipsen Pharma9.6
- Advanced Accelerator Applications (AAA)6.8
- TerSera Therapeutics6.5
- Mallinckrodt Pharmaceuticals12.1
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Treatment Type22.5%
Drug Class15.0%
Tumor Type11.5%
Patient Population24.9%
Treatment Setting26.1%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.9
- Europe22.6
- Asia Pacific19.1
- Latin America14.5
- Middle East and Africa10.8
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Ipsen | 86 | 80 | 97 | 89 | 83 | 79 | 86 |
| Novartis | 84 | 74 | 91 | 84 | 91 | 84 | 85 |
| Ipsen Pharma | 79 | 71 | 65 | 85 | 67 | 82 | 75 |
| Advanced Accelerator Applications (AAA) | 60 | 60 | 78 | 72 | 68 | 57 | 66 |
| TerSera Therapeutics | 64 | 64 | 58 | 53 | 72 | 62 | 62 |
| Mallinckrodt Pharmaceuticals | 60 | 54 | 49 | 64 | 54 | 48 | 55 |
| Novartis AG | 64 | 58 | 52 | 56 | 47 | 62 | 57 |
| Ipsen S.A. | 53 | 46 | 40 | 35 | 50 | 46 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Ipsen
- Novartis
- Ipsen Pharma
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Ipsen | ◐ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Novartis | ✓ | ✓ | ✓ | ◐ | ✓ | ◐ |
| Ipsen Pharma | ◐ | − | ◐ | ✓ | ◐ | ◐ |
| Advanced Accelerator Applications (AAA) | − | ◐ | ◐ | ◐ | ◐ | − |
| TerSera Therapeutics | − | ◐ | − | − | ✓ | ◐ |
| Mallinckrodt Pharmaceuticals | ◐ | − | − | ◐ | ◐ | ◐ |
| Novartis AG | − | − | ◐ | ◐ | − | ◐ |
| Ipsen S.A. | ◐ | − | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Ipsen86
2Novartis85
3Ipsen Pharma75
4Advanced Accelerator Applications (AAA)66
5TerSera Therapeutics62
6Novartis AG57
7Mallinckrodt Pharmaceuticals55
8Ipsen S.A.45
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
IpsenNovartis
Challenger1
Strong scale, closing on the leaders.
Ipsen Pharma
Contender3
Focused players with pockets of strength.
Advanced Accelerator Applications (AAA)TerSera TherapeuticsNovartis AG
Niche2
Specialists in a single segment or region.
Mallinckrodt PharmaceuticalsIpsen S.A.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Treatment Type in North America, then scale across Vasoactive Intestinal Peptide Tumor Treatment Market — a $539M beachhead inside a $8.61B market.
Beachhead (SOM)$539Mobtainable near-term
Serviceable (SAM)$3.16Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Pharmacological Therapy
Best fit — highest urgency & budget in Treatment Type.
Economic buyer79 fit
Surgical Intervention
Strong fit — clear ROI and a fast path to value.
End user67 fit
Radiation Therapy
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Treatment Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Drug Class & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Tumor Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel27%
Digital / self-serve22%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Treatment Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Vasoactive Intestinal Peptide Tumor Treatment Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified21%
Evaluation14%
Closed-won6%
$10.4KCAC
$59KLTV
5.7:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Vasoactive Intestinal Peptide Tumor Treatment Market is a resilient opportunity — $4.93B by 2033, compounding at 3.8%.
TAM · 2025$3.65Btoday
TAM · 2033$4.93Bforecast
CAGR3.8%2027–2033
Cumulative$38.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.93BTotal addressable market
SAM$1.72BServiceable available market
SOM$377MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →3.8% CAGR
Demand compounds through 2033, outpacing GDP across Treatment Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Treatment Type moving from early to mainstream — durable secular demand.
Consolidation upside
10+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.93BLarge & growingTAM by 2033 at 3.8% CAGR
$1.72BServiceable nowreachable with today’s model
$377MBeachhead winobtainable near-term share
10+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.84BBear2.5% CAGR
$4.93BBase3.8% CAGR
$6.31BBull5.0% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Drug Class optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Vasoactive Intestinal Peptide Tumor Treatment Market — a $3.17B market by 2033. Plan: grow share from 7.4% to 13.5%.
Market size · 2033$3.17Btotal addressable
Market CAGR7.7%2027–2033
Target share13.5%from 7.4% today
Revenue ambition$428Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.4% | 13.5% | On track |
| Revenue | $240M | $428M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 30.9% | 45.5% | Behind |
| Customer retention | 89.3% | 93.0% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Treatment Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Drug Class capability
A defensible second engine — invest in Drug Class to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Treatment Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Drug Class
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $57M capacity & capability investment
- Greenlight bolt-on M&A in Drug Class
- Authorise North America expansion plan
- Fund R&D program for Treatment Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossBehind
- Input-cost & supply riskAt risk
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Vasoactive Intestinal Peptide Tumor Treatment Market conversation — a $9.21B market you can size, segment and defend in minutes.
Market size · 2033$9.21Btotal opportunity
Growth11.0%CAGR to 2033
Addressable buyers937+accounts in scope
Typical ROI5.1×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Treatment Type
Goal Grow share in Treatment Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.1×return on cost, year one
< 3 mopayback period
$46K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
10+players profiled in this market
Coverage includes
IpsenNovartisIpsen PharmaAdvanced Accelerator Applications (AAA)TerSera TherapeuticsMallinckrodt PharmaceuticalsNovartis AGIpsen S.A.+2 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Vasoactive Intestinal Peptide Tumor Treatment Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Vasoactive Intestinal Peptide Tumor Treatment Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Vasectomy Device Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportVascular Ultrasound Table Market
Market size, share, segmentation and regional forecast.
$431M market · 2025 base year
View reportVascular Trauma Management Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportVascular Tissue Matrix Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportVascular Suture Devices Market
Market size, share, segmentation and regional forecast.
$794M market · 2025 base year
View reportVascular Surgery Tissue Adhesive Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportVascular Surgery Simulator Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportVascular Surgery Magnifier Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportVascular Surgery Digital Stethoscope Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportVascular Stapler Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportVascular Sheath Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportVascular Sealant Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.